A pharmaceutical composition, comprising: a pharmaceutically acceptable carrier; and a compound of formula (I-A), or a pharmaceutically acceptable salt thereof: wherein: X' is S; X′′′ is unsubstituted phenyl, X" is H or C 1 -C 4 alkyl; R 2 is C 1 -C 4 alkyl; phenyl that is optionally substituted with from 1-4 R e ; or heteroaryl containing from 5-6 ring atoms, wherein from 1-4 of the ring atoms is independently selected from N, NH, N(C 1 -C 3 alkyl), NC(O)(Ci-Ce alkyl), O, and S; and wherein the heteroaryl is optionally substituted with from 1-3 R e ; R 12 is C 2 -C 6 alkoxy that is optionally substituted with -NH 2 ; or heterocyclyl containing from 5-7 ring atoms, wherein from 1-2 of the ring atoms of the heterocyclyl is independently selected from N, NH, N(C 1 -C 6 alkyl), NC(O)(C 1 -C 6 alkyl), NC(O)O(C 1 -C 6 alkyl), O, and S; and each of which is optionally substituted with from 1-3 independently selected C 1 -C 4 alkyl groups; each of R 13 and R 14 is H; and each occurrence of R e is, independently, halo; cyano; -C(O)(C 1 -C 6 alkyl); C(O)OH; - C(O)O(C 1 -C 6 alkyl); -NH 2 ; -NH(C 1 -C 6 alkyl), N(C 1 -C 6 alkyl) 2 , -NHC(O)(C 1 -C 6 alkyl), C 1 -C 6 alkoxy; C 1 -C 6 haloalkoxy; C 1 -C 6 thioalkoxy; C 1 -C 6 thiohaloalkoxy; C 1 -C 6 alkyl, C 3 -C 6 cycloalkyl; or C 1 -C 6 haloalkyl. a pharmaceutically acceptable carrier; and a compound of formula (I-A), or a pharmaceutically acceptable salt thereof: wherein: X' is S; X′′′ is unsubstituted phenyl, X" is H or C 1 -C 4 alkyl; R 2 is C 1 -C 4 alkyl; phenyl that is optionally substituted with from 1-4 R e ; or heteroaryl containing from 5-6 ring atoms, wherein from 1-4 of the ring atoms is independently selected from N, NH, N(C 1 -C 3 alkyl), NC(O)(Ci-Ce alkyl), O, and S; and wherein the heteroaryl is optionally substituted with from 1-3 R e ; R 12 is C 2 -C 6 alkoxy that is optionally substituted with -NH 2 ; or heterocyclyl containing from 5-7 ring atoms, wherein from 1-2 of the ring atoms of the heterocyclyl is independently selected from N, NH, N(C 1 -C 6 alkyl), NC(O)(C 1 -C 6 alkyl), NC(O)O(C 1 -C 6 alkyl), O, and S; and each of which is optionally substituted with from 1-3 independently selected C 1 -C 4 alkyl groups; each of R 13 and R 14 is H; and each occurrence of R e is, independently, halo; cyano; -C(O)(C 1 -C 6 alkyl); C(O)OH; - C(O)O(C 1 -C 6 alkyl); -NH 2 ; -NH(C 1 -C 6 alkyl), N(C 1 -C 6 alkyl) 2 , -NHC(O)(C 1 -C 6 alkyl), C 1 -C 6 alkoxy; C 1 -C 6 haloalkoxy; C 1 -C 6 thioalkoxy; C 1 -C 6 thiohaloalkoxy; C 1 -C 6 alkyl, C 3 -C 6 cycloalkyl; or C 1 -C 6 haloalkyl. X' is S; X′′′ is unsubstituted phenyl, X" is H or C 1 -C 4 alkyl; R 2 is C 1 -C 4 alkyl; phenyl that is optionally substituted with from 1-4 R e ; or heteroaryl containing from 5-6 ring atoms, wherein from 1-4 of the ring atoms is independently selected from N, NH, N(C 1 -C 3 alkyl), NC(O)(Ci-Ce alkyl), O, and S; and wherein the heteroaryl is optionally substituted with from 1-3 R e ; R 12 is C 2 -C 6 alkoxy that is optionally substituted with -NH 2 ; or heterocyclyl containing from 5-7 ring atoms, wherein from 1-2 of the ring atoms of the heterocyclyl is independently selected from N, NH, N(C 1 -C 6 alkyl), NC(O)(C 1 -C 6 alkyl), NC(O)O(C 1 -C 6 alkyl), O, and S; and each of which is optionally substituted with from 1-3 independently selected C 1 -C 4 alkyl groups; each of R 13 and R 14 is H; and each occurrence of R e is, independently, halo; cyano; -C(O)(C 1 -C 6 alkyl); C(O)OH; - C(O)O(C 1 -C 6 alkyl); -NH 2 ; -NH(C 1 -C 6 alkyl), N(C 1 -C 6 alkyl) 2 , -NHC(O)(C 1 -C 6 alkyl), C 1 -C 6 alkoxy; C 1 -C 6 haloalkoxy; C 1 -C 6 thioalkoxy; C 1 -C 6 thiohaloalkoxy; C 1 -C 6 alkyl, C 3 -C 6 cycloalkyl; or C 1 -C 6 haloalkyl. <EOS>